Attached files
| file | filename |
|---|---|
| EX-10.12 - EXHIBIT 10.12 ACEARNAL 2017 - CUMBERLAND PHARMACEUTICALS INC | a2016-10kxexhibit1012marti.htm |
| 10-K - 10-K 2016 - CUMBERLAND PHARMACEUTICALS INC | a2016-10k.htm |
| EX-31.2 - EXHIBIT 31.2 2016 10K - CUMBERLAND PHARMACEUTICALS INC | a2016-10kxexhibit312.htm |
| EX-31.1 - EXHIBIT 31.1 EXHIBIT 31.1 2016 - CUMBERLAND PHARMACEUTICALS INC | a2016-10kxexhibit311.htm |
| EX-23.1 - EXHIBIT 23.1 CONSENT OF KPMG 2016 - CUMBERLAND PHARMACEUTICALS INC | a2016-10kxexhibit231consen.htm |
| EX-10.33.2 - EXHIBIT 10.33.2 2ND AMENDMENT DEBT - CUMBERLAND PHARMACEUTICALS INC | a2016-10kxexhibit10332x2nd.htm |
| EX-10.15 - EXHIBIT 10.15 JHERMAN 2017 - CUMBERLAND PHARMACEUTICALS INC | a2016-10kxexhibit1015jimhe.htm |
| EX-10.14 - EXHIBIT 10.14 MBONNER 2017 - CUMBERLAND PHARMACEUTICALS INC | a2016-10kxexhibit1014micha.htm |
| EX-10.13 - EXHIBIT 10.13 LPAVLIV 2017 - CUMBERLAND PHARMACEUTICALS INC | a2016-10kxexhibit1013leopa.htm |
| EX-10.11 - EXHIBIT 10.11 AJKAZIMI 207 - CUMBERLAND PHARMACEUTICALS INC | a2016-10kxexhibit1011ajkaz.htm |
Exhibit 32.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
AND CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Cumberland Pharmaceuticals Inc. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, A.J. Kazimi, Chief Executive Officer, and Michael Bonner, Senior Director and Chief Financial Officer, of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. section 1350), that, based on my knowledge:
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ A.J. Kazimi | |
A.J. Kazimi | |
Chief Executive Officer | |
March 10, 2017 | |
/s/ Michael Bonner | |
Michael Bonner | |
Senior Director and Chief Financial Officer | |
March 10, 2017 | |